Approved supplement to the prospectus of the public

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
82
Approved supplement to the prospectus of the public offering of INVL Baltic Real Estate

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE STOCK EXCHANGE RELEASE.

On 21 May 2018 Director of the Supervision Service of the Bank of Lithuania by the decision No. 241-128 approved the supplement to the prospectus of the public offering (hereinafter, the “Supplement to the Prospectus”, please see the attached documents) of INVL Baltic Real Estate  (hereinafter, the “Company”). The Prospectus of INVL Baltic Real Estate  was approved by the Bank of Lithuania and  published by the Company on 23 April 2018 (decision regarding approval of the Prospectus No. 241-70, the “Prospectus”). The supplement to the Prospectus is an integral part of the Prospectus and must be read in conjunction with the entire Prospectus and the documents incorporated by reference to the Prospectus.

This Supplement has been approved and announced taking into consideration the position of the Bank of Lithuania regarding the possibility for the management company to execute the secondary public offering of listed shares of a closed-ended investment company under the Law of the Republic of Lithuania on Collective Investment Undertakings, when the shares, held by one of the investors (shareholders) of the closed-ended investment company are offered. Thus, under such circumstances, the offering broker of the offering had to be changed (selected). INVL Finasta UAB FMĮ was appointed as the offering broker, executing the offering under the Prospectus. The Supplement to the Prospectus reflects these necessary  amendments.

All other conditions remain unchanged and are the same as stated in the material event of the approval of the Prospectus published by the Company on 23 April 2018, i.e. the Public offering  is executed by Invalda INVL AB (hereinafter referred, the „Selling Shareholder“), which on the day of the Prospectus and on this announcement day is the largest shareholder of the Company. During the Public Offering, the Selling Shareholder sells up to 2,893,000 units of existing ordinary registered shares of the Company, which represent up to 22% of the Company's share capital.

According to the Prospectus (also taking into account the Supplement to the Prospectus), the Offering consists of Public Offering in the Republic of Lithuania; and a private placement to Institutional Investors outside of the United States of America (excluding Lithuania) in reliance on Regulation S under the U.S. Securities Act of 1933. The Offering also covers private offering of Offer Shares to individually identified non-institutional and non-qualified investors.

The Public Offering price:

The Public Offering shares are being offered at the Public Offering Price (hereinafter, the “Offer Price”), which is established based on this formula:

OP = NAV/Shares, where

OP – Offer Price applicable to the particular Offering Period;

NAV – the latest Net Asset Value (the difference between the value of assets owned by the Company and long-term and current liabilities of the Company), which was announced prior to commencement of the particular Offering Period;

Shares – number of outstanding Shares of the Company (13,150,000).

The Offer Price is the same for all the Investors. However, taking into consideration that following the requirements of the applicable legal acts and the Articles of Association, the calculations of the Net Asset Value is performed and announced at least once per three months, the Offer Price during the different Offering Periods may be different (depending on the announced NAV). In any case it will be ensured, that during the same Offering Period the Offer Price calculated based on the above formula shall be the same.

Expected Public Offering Periods  (Acceptance of the Purchase Orders from the Investors) :

- from 2 May 2018 till 4 July 2018 (from 9 a.m. until 5 p.m. Vilnius time); - from 18 August 2018 till 18 September 2018 (from 9 a.m. until 5 p.m. Vilnius time); - from 2 November 2018 till 13 December 2018 (from 9 a.m. until 5 p.m. Vilnius time).

The Selling Shareholder reserves the right to change the timetable of the Periods of the Public Offering. Should the Selling Shareholder decide to materially adjust the dates set out in the timetable, the relevant supplement to the Prospectus will be provided to the Bank of Lithuania for the approval and published (upon the approval) in compliance with applicable regulations, as well as market practices in Lithuania.

Details of the submission and payment of the purchase orders, as well as other Public Offering Conditions, are indicated in the Prospectus (also taking into account the Supplement to the Prospectus).

IMPORTANT NOTICE:

This notification is not for distribution to United States newswire services or for dissemination in the United States, Canada, Japan or Australia or elsewhere where such dissemination is not appropriate.

Distribution of this announcement and other information in connection with the Company may be restricted by law in certain jurisdictions. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions.

No offer or invitation to acquire securities of the Company is being made by or in connection with this notification. Any such offer is made solely by means of the Prospectus (also taking into account the Supplement to the Prospectus) and the Prospectus (also taking into account the Supplement to the Prospectus) is the only legally binding document containing information on the Company and on the Company’s shares. The Prospectus (also taking into account the Supplement to the Prospectus) is published through GlobeNewswire, the on-line information system of AB Nasdaq Vilnius, and on the Company’s website  www.invlbalticrealestate.lt  and (for information purposes only) on the management company's website at  www.invl.com .

In addition, the Prospectus (also taking into account the Supplement to the Prospectus) has been prepared on the grounds that there will be no public offering of the shares of the Company, except for a public offering in the Republic of Lithuania in accordance with the 2003 Act. November 4 Directive 2003/71 / EC of the European Parliament and the Council on the Prospectus to be published when shares are offered to the public or admitted to trading and amending Directive 2001/34 / EC as implemented by Lithuania.

The securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended, and may not be offered or sold in the United States or to US persons unless the securities are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act is available. No public offering of the securities will be made in the United States.

The person authorized to provide additional information:          Real Estate Fund Manager of Management Company          Vytautas Bakšinskas          E-mail vytautas.baksinskas@invl.com

Attachments

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Zenas BioPharma Investors Urged to Join Class Action Lawsuit

Updated Category News Views 119

Overview of the Class Action Lawsuit Levi & Korsinsky, LLP is reaching out to investors in Zenas BioPharma, Inc. regarding a crucial class action lawsuit. This lawsuit may greatly impact those who have invested in Zenas BioPharma as it seeks to compensate individuals who have suffered losses due to alleged securities fraud. Understanding the Legal Landscape This class...

Continue Reading
Ayar Labs Raises $155 Million to Transform AI Infrastructure

Updated Category News Views 716

Ayar Labs Secures Significant Funding to Enhance AI Infrastructure Ayar Labs has recently secured $155 million in financing aimed at addressing the critical needs in AI infrastructure. With backing from prominent investors such as AMD Ventures, Intel Capital, and NVIDIA, alongside Advent Global Opportunities and Light Street Capital, this investment elevates the total...

Continue Reading
Transforming the Non-Profit Sector: The Impact Collaborative

Updated Category News Views 159

Impact Collaborative Launches to Transform the Non-Profit Sector Today marks a significant milestone with the launch of the Impact Collaborative (IC), a pioneering initiative aimed at revolutionizing the support provided to under-resourced communities. This innovative approach seeks to disrupt generational poverty while offering much-needed access to mental health and...

Continue Reading
Synovus Financial Corp Declares Quarterly Dividends for Investors

Updated Category News Views 128

Synovus Financial Corp Declares Quarterly Dividends Synovus Financial Corp. (NYSE: SNV) has recently revealed the details of its latest quarterly dividends. The board of directors has approved significant payouts to its shareholders, reinforcing the company’s ongoing commitment to deliver value to its investors. Details of the Declared Dividends The following dividends...

Continue Reading
Walnut Hill Medical Enhances Patient Access Through FDA TAP Program

Updated Category News Views 171

Walnut Hill Medical Partners with FDA in TAP Program Walnut Hill Medical, a prominent healthcare consultancy known for its market access and reimbursement strategies, has been chosen as an advisor to the FDA's Total Product Life Cycle Advisory Program (TAP). This initiative, which originated from the FDA's Center for Devices and Radiological Health (CDRH), aims to improve...

Continue Reading